Freenome, Inc.

Freenome, Inc.

FRNM

Get informed when a big investor buys or sells

+ Follow
Market Cap$128.72M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Freenome, Inc.Freenome, Inc.0-12%--
$18.25

Target Price by Analysts

45.2% upsideFreenome Target Price DetailsTarget Price

Share Statistics

Market cap$128.72 Million
Enterprise Value$128.28 Million
Dividend Yield$- (NaN%)
Earnings per Share$-
Beta0.35
Outstanding Shares-

Return

Return on Equity12.11%ROE
Return on Assets-0.89%
Return on Invested Capital-4.26%

Valuation & Multiples

P/E Ratio-P/E Ratio
PEG-PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue155.24
Enterprise Value to EBIT-36.6
Enterprise Value to Net Income-169
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 15, 2026
EPS Estimate
$-1.77
Average shareholder expectation
Revenue Estimate
$3.02 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 10, 2026
EPS Estimate
$0.14
Average shareholder expectation
Revenue Estimate
$84.94 M
Average shareholder expectation

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

ESG Score

No data

About Perceptive Capital Solutions Corp

378 employees
CEO: Aaron Elliott

Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA me...